(GKOS) Glaukos Corporation BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(GKOS) Glaukos Corporation Complete Analysis Pack
Unlock Strategic Clarity
This Glaukos Corporation BCG Matrix helps you understand how the company’s products or business units are positioned across the four classic quadrants for strategy and portfolio planning. The page already shows a real preview of the actual analysis, so you can review the content and format before buying. Purchase the full version to get the complete ready-to-use report.
Stars
iStent inject W, 3rd-gen MIGS
iStent inject W is Glaukos Corporation's most established glaucoma implant line and a Star in its BCG mix; the company says it has been used in over 1.5 million procedures worldwide. It fits the fast-growing minimally invasive glaucoma surgery market, which is expanding as surgeons favor lower-risk, cataract-linked use. Repeat adoption is strong because surgeons know the platform and can place it during routine cataract cases.
iStent family, 2012-2025 glaucoma platform
iStent is Glaukos Corporation’s flagship franchise, launched in 2012 and still the core brand in minimally invasive glaucoma surgery. Its wide recognition in open-angle glaucoma supports repeat use by surgeons and helps defend share as the treated patient pool keeps growing. In Glaukos Corporation’s 2025 base, this brand equity still matters most because it anchors the company’s largest, most established platform.
Open-angle glaucoma, core addressable market
Open-angle glaucoma is Glaukos Corporation’s core addressable market, and it anchors the company’s surgery and implant model. With MIGS adoption rising and glaucoma affecting an estimated 80 million people worldwide, the open-angle segment is Glaukos’s largest clinical end market. Its leadership in iStent and related implants gives this area Star-like traits: scale, growth, and strong share.
U.S. direct sales force, specialty-device channel
Glaukos uses its own U.S. sales force to train surgeons and support cases, which helps turn demand into procedure volume in a hard-to-sell device market. In 2025, that direct channel stayed a growth asset, not just a back-office cost, because complex glaucoma and corneal procedures need real-time clinical and reimbursement support.
- Direct training speeds surgeon adoption.
- Case support raises conversion rates.
- Specialty focus fits complex devices.
- Sales force drives repeat procedure growth.
International MIGS rollout, distributor network
Glaukos Corporation sells outside the U.S. through distributors, and that channel still leaves room for MIGS adoption to rise in Europe, Asia, and Latin America. In FY2025, international sales were still a smaller base than the U.S., so each new market can add incremental growth without needing a mature domestic market. That gives the MIGS franchise a longer runway than a U.S.-only business.
- Distributor model lowers launch costs
- International MIGS adoption is still early
- More geographies mean more upside
iStent inject W Powers Glaukos’ Growth in MIGS
iStent inject W remains Glaukos Corporation’s Star: it has been used in over 1.5 million procedures and sits in the fastest-growing MIGS lane. Open-angle glaucoma, with about 80 million patients worldwide, gives the franchise a large runway. Glaukos Corporation’s direct U.S. sales force helps convert surgeon interest into repeat use.
| Metric | Data |
|---|---|
| Procedures | 1.5M+ |
| Global glaucoma patients | 80M |
| Channel | Direct U.S. force |
What is included in the product
Detailed Word Document
Glaukos BCG Matrix maps its eye-care products by growth and share, highlighting invest, hold, and divest priorities.
Editable Excel File
One-page Glaukos BCG Matrix to quickly spot stars, cash cows, and underperformers.
Reference Sources
Provides a concise source trail for Glaukos Corporation, boosting credibility and speeding confident decisions.
Cash Cows
Photrexa + KXL, keratoconus CXL
Photrexa + KXL is Glaukos Corporation’s mature corneal cross-linking cash cow: it was the first U.S. FDA-approved CXL platform and now has an established installed base. In FY2025, the franchise kept generating steady procedure demand with lower launch risk than newer products, making it a dependable source of operating cash. Its role is defensive and profitable, not high-growth.
iStent inject, 2-stent predecessor
iStent inject, the 2-stent predecessor, still adds commercial volume for Glaukos Corporation, but the newer iStent inject W is the clearer growth driver. That makes the older system a harvested asset: it can keep selling, yet it has less room to expand and likely grows below the Company Name’s newer implant portfolio.
Legacy iStent, first-gen micro-bypass
Legacy iStent, Glaukos Corporation's first-gen micro-bypass, built the franchise and helped seed the MIGS market. It is now mature, so demand is steadier than new products and it fits a cash-cow profile. Glaukos launched iStent in 2012, and the platform has since shifted from growth engine to harvest asset.
KXL installed base, repeat utilization
KXL fits the cash cow profile because each installed corneal footprint can keep driving repeat cross-linking use with limited added selling cost. Glaukos does not break out KXL installed-base revenue, but the model stays attractive because the system monetizes procedure repetition after the first placement, which is the kind of low-growth, high-cash dynamic BCG labels a cash cow.
- Installed base supports repeat use
- Lower incremental selling expense
- Procedure revenue can recur
- Cash flow rises without new installs
Mature ex-U.S. distributor markets
Glaukos Corporation’s mature ex-U.S. distributor markets fit a cash-cow profile: the company already has an established international channel, so growth needs less heavy promotion and sales can stay steadier. In 2025, that kind of base matters more as Glaukos keeps monetizing its implanted glaucoma and corneal products outside the U.S.
- Established distributor reach
- Lower promo spend
- Steadier ex-U.S. revenue
- Cash-generation profile
Glaukos’ Cash Cows Keep the Cash Flowing
Glaukos Corporation’s cash cows are its mature franchises: Photrexa + KXL, legacy iStent, and the older iStent inject. In FY2025, these lines likely delivered steady procedure volume and cash with limited new-launch spend, so growth was modest but margin support stayed strong. Their value is harvest income, not fast expansion.
| Cash cow | FY2025 signal |
|---|---|
| Photrexa + KXL | Repeat CXL use |
| Legacy iStent | Mature volume |
| iStent inject | Harvested asset |
Preview Before You Purchase
Glaukos Corporation Reference Sources
The Glaukos Corporation BCG Matrix preview you’re viewing is the exact same document you’ll receive after purchase. No mockups, no filler—just the complete, professionally formatted report. It’s ready for immediate use in analysis, presentations, or strategic planning. Download it once, and the full file is yours.
Dogs
First-gen iStent, 2012 legacy
The first-gen iStent, launched in 2012, is a legacy MIGS implant that has been overtaken by newer Glaukos devices like iStent inject and iStent infinite. Its growth runway is now limited, and its role in the portfolio is shrinking as newer implants drive adoption and revenue. In BCG terms, it fits a Dog: low growth, low strategic priority, and likely only cash harvest value.
Older product variants, low-volume SKUs
Older Glaukos Corporation specialty-device variants can fit the dog bucket because they often sit at low volume with little growth. They still consume inventory, service, and regulatory effort, while low share and low demand cap returns. If a SKU is not moving in FY2025/FY2026, it is usually a drag, not a driver.
Thin-share geographies, low penetration regions
Thin-share geographies are Dogs for Glaukos Corporation because MIGS adoption stays slow when reimbursement is weak and surgeon awareness is low. Those regions usually add little to growth, especially when Glaukos Corporation can’t scale share quickly across its broader 2025 base. If demand stays thin, extra sales force spend rarely pays back.
Non-core corneal adjacencies, mature side products
Glaukos Corporation’s non-core corneal adjacencies are mature side products that do not benefit from the same scale economics as the core corneal franchise. When they fail to lift share or margin, they act like dogs, so management usually keeps selling and R&D spend tight and lets cash flow drive the decision. That keeps capital focused on higher-growth corneal and glaucoma platforms.
- Low growth, weak scale
- Minimal spend, limited priority
- Risk of margin drag
Sunset inventory, phased-out implants
Phased-out implants can still sit in Glaukos Corporation’s distribution pipeline, so they tie up working capital and add storage and handling costs without much strategic upside. That fits a Dogs profile: low growth, low share, and weak return on capital.
- Inventory lingers after phase-out.
- Costs stay, sales fade.
- Low-growth, low-share Dog.
Glaukos Dogs: Harvest Legacy iStent, Cut Weak-Scale Spend
Glaukos Corporation’s Dogs are legacy iStent SKUs, thin-share geographies, and other low-growth adjacencies that now add more cost than growth. They still use inventory, sales, and regulatory effort, but newer iStent products and core franchises get the capital. In BCG terms, these assets are best treated as cash-harvest or phase-out items.
| Dog area | Signal | Action |
|---|---|---|
| Legacy iStent | Low growth | Harvest |
| Thin-share regions | Weak scale | Limit spend |
Question Marks
iDose TR, FDA 2023 implant
iDose TR was FDA approved in 2023 and entered commercialization soon after, so it is still in the build phase. The glaucoma drug-delivery market is attractive because treatment is chronic and adherence is weak, but Glaukos is still scaling awareness, reimbursement, and surgeon adoption. That fits a classic question mark: high market potential, but low current share and heavy launch spending.
iStent infinite, 3-stent standalone system
iStent infinite is a 3-stent standalone system for refractory glaucoma after prior surgery failure, so it fits a niche with clear clinical need but a limited patient pool. Glaukos launched it in 2022, and by 2025 it was still in the share-building stage rather than a scale leader. That makes it a Question Mark: real growth runway, but adoption is still being earned.
Epioxa, next-gen corneal cross-linking
Epioxa is Glaukos Corporation’s next-gen corneal cross-linking bet, aimed at extending the corneal franchise beyond the mature KXL base. It is still a development asset, so there is no commercial revenue yet and no proof it can lead the market. If it works, it could open a larger addressable market than KXL alone.
Retina pipeline, pre-commercial programs
Glaukos Corporation’s retina pipeline sits in question-mark territory because the opportunity is large, but commercial scale is still limited. The global retinal disease market spans millions of patients, including diabetic macular edema and wet AMD, yet Glaukos’s retina work has not matched its stronger glaucoma franchise in revenue scale.
That means upside is real, but adoption, trial execution, and reimbursement still drive the outcome.
- Large market; low current scale
- High upside; early commercial stage
- Still a question mark in BCG terms
Standalone glaucoma drug delivery, new growth pool
Standalone glaucoma drug delivery opens Glaukos Corporation to a much bigger market than implant surgery alone; glaucoma affects about 80 million people worldwide. But share is still small, so this unit fits the Question Mark quadrant and needs more spend to scale into a Star.
- Big market, low current share
- New growth beyond implants
- Needs capital to scale fast
Glaukos’ Big Bets: High Upside, Early-Stage Risk
Glaukos Corporation’s question marks are iDose TR, iStent infinite, Epioxa, and retina. They have clear growth upside, but each is still early in adoption, so share is low versus the spend needed to win surgeons, payers, and patients.
Glaucoma affects about 80 million people worldwide, but Glaukos is still building scale in drug delivery and standalone surgery. That mix fits the BCG Question Mark quadrant: big market, uncertain monetization, and heavy launch risk.
| Asset | Status | BCG read |
|---|---|---|
| iDose TR | FDA approved 2023 | Question Mark |
| iStent infinite | Launched 2022 | Question Mark |
| Epioxa | Development stage | Question Mark |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.